Full text is available at the source.
Abstract
GLP-1 receptor agonists liraglutide and exenatide may significantly reduce cardiovascular risk factors in patients with type 2 diabetes.
- Liraglutide and exenatide effectively lower blood sugar levels in patients with type 2 diabetes.
- These medications are associated with significant weight loss and a reduction in systolic blood pressure.
- Improvements in lipid levels have been observed with the use of GLP-1 receptor agonists.
- In vitro studies and animal models suggest potential direct effects of GLP-1 receptor agonists on heart cells and blood vessel lining.
Simplified